A polymorphism in the CYP17 gene is associated with male breast cancer

Young, Irene; Kurian, Kathreena M.; Annink, C; Kunkler, I.; Anderson, Victoria A.; Cohen, Brian; Hooper, Martin; Wyllie, Andrew H.; Steel, C. M.

doi:10.1038/sj.bjc.6690663

Cited by 76 publications

(54 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…9) The association was not observed for Caucasians in the United States, 4,5,7) in the United Kingdom, 6,10) and in Norway, 8) or Chinese in Taiwan. 11) The present study adds the finding that breast cancer risk is not high for the CC-genotype among Japanese. A meta-analysis of four studies [3][4][5][6] concluded that the relative risk was 1.5 or smaller for the CYP17 polymorphism on average.…”

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

“…To date, several studies have examined the association of the polymorphism with breast cancer risk, but the results were inconsistent. [3][4][5][6][7][8][9][10][11] Although the incidence of breast cancer in Japan is only one-fifth of that in the United States, it has been increasing since 1960s. 12) Second-generation Japanese Americans in Hawaii and Los Angeles have the same level of breast cancer incidence as other Americans, indicating that lifestyle plays an important role in breast cancer carcinogenesis.…”

mentioning

confidence: 99%

See 2 more Smart Citations

No Association of the 5′Promoter Region Polymorphism of CYP17 with Breast Cancer Risk in Japan

Hamajima¹,

Iwata

Obata

et al. 2000

Japanese Journal of Cancer Research

View full text Add to dashboard Cite

To examine the association between breast cancer risk and a T-to-C substitution polymorphism at the 5′ ′ ′ ′ promoter region of CYP17, a case-control study was conducted at Aichi Cancer Center Hospital in Japan. Subjects were 144 histologically confirmed breast cancer patients diagnosed in the past 4 years and 166 hospital controls without cancer. Allele frequency among controls was 44.9% (95% confidence interval; 39.5-50.2) for C allele. Odds ratio (OR) of the polymorphism relative to TT-genotype was 0.97 (0.58-1.64) for TC-genotype and 0.81 (0.39-1.68) for CC-genotype. Subgroup analyses revealed that the OR was not statistically significant for the subgroups stratified by interval after diagnosis, age at menarche, age at first birth, menopausal status, body mass index, and mother/sisters' history of breast cancer. Consistent with previous studies conducted in other countries, the 5′ ′ ′ ′ promoter region polymorphism of CYP17 affected breast cancer risk of Japanese women to a limited extent. Although this is not a large-scale case-control study with population controls, these findings provide enough information to discourage further studies on the association between this polymorphism and breast cancer risk in Japan at large, and suggest that this polymorphism is useless for breast cancer risk estimation.Key words: Breast cancer -CYP17 -Polymorphism -Case-control study CYP17 gene located on chromosome 10q24.3 encodes an enzyme, cytochrome p450c17, which has two different roles in steroid hormone metabolism; 17α-hydroxylase and 17,20-lyase activities. The former converts pregnenolone to 17-hydroxypregnenolone and progesterone to 17-hydroxyprogesterone, and the latter further converts the metabolites to dehydroepiandrosterone and androstenedione, respectively. 1) Since this enzyme is essential for estrogens synthesis, increased or decreased activities are speculated to modify the risk of breast cancer. A single nucleotide polymorphism (T-to-C transition) of CYP17 at 34 bp upstream of the translation initiation site in the 5′ untranslated region was reported to create an additional Sp1-type (CCACC box) promoter site, 2) which suggested an increased rate of transcription and possibly a consequent increase in activity of estrogens. To date, several studies have examined the association of the polymorphism with breast cancer risk, but the results were inconsistent. [3][4][5][6][7][8][9][10][11] Although the incidence of breast cancer in Japan is only one-fifth of that in the United States, it has been increasing since 1960s.12) Second-generation Japanese Americans in Hawaii and Los Angeles have the same level of breast cancer incidence as other Americans, indicating that lifestyle plays an important role in breast cancer carcinogenesis. However, similarly important are genetic factors which modify the effects of lifestyle factors. In Japan, there have been few studies on the association between genetic polymorphisms and breast cancer risk. This is a case-control study to examine the association of the 5′ promoter re...

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

No Association of the 5′Promoter Region Polymorphism of CYP17 with Breast Cancer Risk in Japan

Hamajima¹,

Iwata

Obata

et al. 2000

Japanese Journal of Cancer Research

View full text Add to dashboard Cite

show abstract

“…This enzyme has both 17-α-hydroxylase and 17,20-lyase activities, and is involved in the production of estrogen (Picado-Leonard et al, 1987). CYP17 gene polymorphisms may be related with numerous tumors, including breast cancer (Feigelson et al, 1997;Bergman-Jungestrom et al, 1999;Young et al, 1999) and prostate cancer (Habuchi et al, 2000). The CYP17 A1 allele polymorphism has an androgenic effect upon male individuals and is associated with an increased risk of prostate cancer and benign prostatic hyperplasia (Habuchi et al, 2000).…”

Section: Discussionmentioning

confidence: 99%

Cytochrome P450c17alpha (CYP17) gene polymorphism is not associated with leiomyoma susceptibility

et al. 2002

View full text Add to dashboard Cite

Estrogen plays a role in the pathogenesis of leiomyoma. The CYP17 gene codes for the cytochrome P450c17α enzyme, which is involved in the biosynthesis of estrogen. Our aim was to investigate if CYP17 polymorphism could be a useful marker to predict the susceptibility to leiomyoma. Our sample of female subjects was divided into two groups: (1) with leiomyoma (n = 159); (2) without leiomyoma (n = 128). A 169-bp fragment encompassing the A1/A2 polymorphic site of the CYP17 gene was amplified by polymerase chain reaction (PCR), restricted by enzyme MspA1I and electrophored on agarose gel. Genotypes and allelic frequencies for this polymorphism in both groups were compared. There was no significant difference between the two groups regarding the distribution of the CYP17 gene polymorphism frequencies. The A1 homozygote/heterozygote/A2 homozygote proportions for CYP17 in both groups were: (1) 17.0/46.5/36.5%, and (2) 17.2/45.3/37.5%. The proportions for alleles A1 and A2 were also comparable in the two groups. A1 and A2 allele frequencies were: 7% (40.3/59) in group 1, and 2% (39.8/60) in group 2. No significant association was observed between the risk of leiomyoma and polymorphisms of the CYP 17 gene. So, CYP17 gene polymorphism does not appear to be a useful marker for the prediction of leiomyoma susceptibility.

show abstract

“…Control DNA samples were obtained from 79 healthy males representative of the South East Scotland population. Further details of male breast cancer cases and controls have previously been described (Young et al, 1999). Ethical approval for the study was obtained through the Lothian Regional Ethics Committee.…”

Section: Case and Control Population Selectionmentioning

confidence: 99%

A polymorphic tetranucleotide repeat in the CYP19 gene and male breast cancer

et al. 2000

Self Cite

View full text Add to dashboard Cite

show abstract

A polymorphism in the CYP17 gene is associated with male breast cancer

Abstract: SummaryThe CYP17 gene codes for the cytochrome P450c17α enzyme that is involved in the synthesis of oestrogens. This case-control study from the South East of Scotland shows that a polymorphism of the CYP17 gene is associated with an increased risk of male breast cancer.

Cited by 76 publications

References 11 publications

No Association of the 5′Promoter Region Polymorphism of CYP17 with Breast Cancer Risk in Japan

No Association of the 5′Promoter Region Polymorphism of CYP17 with Breast Cancer Risk in Japan

Cytochrome P450c17alpha (CYP17) gene polymorphism is not associated with leiomyoma susceptibility

A polymorphic tetranucleotide repeat in the CYP19 gene and male breast cancer

Contact Info

Product

Resources

About